Endometrial lesions after tamoxifen therapy in breast cancer women

Breast Journal

Volumn 7, Issue 4, 2001, Pages 240-244

  Maugeri, Giovanni ^a,b   Nardo, Luciano G ^a   Campione, Claudio ^a   Nardo, Filadelfo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Ascoli Tomaselli Hospital   (Italy)

Author keywords

Biopsy; Breast cancer; Endometrial lesions; Hysteroscopy; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RISK; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; POLYP; POSTMENOPAUSE;

BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; HYSTEROSCOPY; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN;

EID: 0034793827     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2001.20038.x     Document Type: Article

References (38)

1. Recent trends in US breast cancer incidence, survival, and mortality rates
2. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study
3. New endocrine treatments for breast cancer: Biological and clinical aspects
4. Tamoxifen and other antioestrogens
5. Results of the Cancer Research Campaign adjuvant trial for perioperative cyclophosphamide and long term tamoxifen in early breast cancer reported at the tenth year of follow-up
6. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy
7. Effect of long term tamoxifen treatment on bone turnover in women with breast cancer
8. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
9. The short term effect of tamoxifen on bone turnover in older women
10. Coronary heart disease mortality and adjuvant tamoxifen therapy
11. After the menopause: Tamoxifen and other new prevention maintenance therapies
12. Blood chemistry profiles in menopausal women administered tamoxifen for breast cancer
13. Tamoxifen and liver damage
14. Adjuvant tamoxifen and second cancers
15. Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects
16. Hysteroscopic follow-up during tamoxifen treatment
17. Symptoms associated with tamoxifen treatment in postmenopausal women
18. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
19. Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use
20. Second cancers after adjuvant tamoxifen therapy for breast cancer
21. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
22. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery
23. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen
24. Uterine carcinosarcoma in association with tamoxifen therapy
25. Tamoxifen and the uterus and endometrium
26. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy
27. Tamoxifen and benign endometrial lesions
28. Tamoxifen and uterine fibroids
29. Prolonged survival by "early" salvage treatment of breast cancer patients: A retrospective 6-year study
30. Diagnostic hysteroscopy after breast cancer and complementary therapy with tamoxifen
31. Ultrasound in gynecology: Endometrium
32. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen: A transvaginal ultrasound study
33. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
34. Uterine surveillance of asymptomatic postmenopausal women on long term tamoxifen
35. Descriptive clinico-pathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer
36. Endometrial lesions in patients undergoing tamoxifen therapy
37. Tamoxifen and uterine pathology
38. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen